Pilot study of MK-462 in migraine

Cephalalgia

Volumn 16, Issue 2, 1996, Pages 113-116

  Cutler, N R ^a,d   Claghorn, J ^b   Sramek, J J ^a   Block, G ^c   Panebianco, D ^c   Cheng, H ^c   Olah, T V ^c   Reines, S A ^c  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b Clinical Research Associates   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NONE   (United States)

Author keywords

5HT(1D) receptor agonist; MK 462

Indexed keywords

PLACEBO; RIZATRIPTAN; SEROTONIN AGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; ORAL DRUG ADMINISTRATION; VERTIGO; XEROSTOMIA;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; PILOT PROJECTS; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES;

EID: 0029868628     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1996.1602113.x     Document Type: Article

References (22)

1. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993;43:516-20
2. Humphrey PP. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 1991;238:S38-44
3. Moskowitz MA, MacFarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993;5:159-77
4. Saxena PR, Ferrari MD. From serotonin receptor classification to the antimigraine drug sumatriptan. Cephalalgia 1992;12: 187-96
5. 1D receptor agonism predicts antimigraine efficacy. Headache 1991;31: 228-31
6. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47:622-51
7. 1-like receptor agonist. Br J Pharmacol 1989;96:379-87
8. Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Br J Pharmacol 1989;96:83-90
9. 1-like receptors mediate 5-hydroxytryptamine-induced action of GR 43175 in anaesthetized dogs. Br J Pharmacol 1989;96:434-49
10. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extra-vasation from blood vessels in dura mater. Br J Pharmacol 1990;99:202-6
11. 1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991;11:165-8
12. Peroutka SJ. Developments in 5-hydroxytryptamine receptor pharmacology in migraine. Neurol Clin 1990;8:829-39
13. 1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development. Proc Natl Acad Sci USA 1994;91:3666-9
14. Dixon CM, Saynor DA, Andrew PD, et al. Disposition of sumatriptan in laboratory animals and humans. Drug Metab Dispos Biol Fate Chem 1993;21:761-9
15. Cutler NR, Hussey EK, Sramek JJ, et al. Oral sumatriptan in pharmacokinetics in the migrainous state. Proceedings of the Fifth International Headache Congress. Cephalalgia 1991; 11(S11):222-3
16. Sargent J, Kirchner JR, Davis R, Kirkhart B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 1995;45 Suppl 7:S10-14
17. Cutler NR, Mushet GR, Davis R, Clements B, Whitcher L. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995;45 Suppl 7:S5-9
18. 1D agonist. Clin Pharm Ther 1994;55:129
19. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988;8:19-28
20. 1D agonists MK-462 and sumatriptan in plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. J Chromatography (in press)
21. Oral sumatriptan dose-defining study group. Sumatriptan: an oral dose-defining study. Eur Neurol 1991;31:300-5
22. Oral sumatriptan international multiple-dose study group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:306-13